Previous estimates had put this risk closer to ... Master Regulator Blocking Immunotherapy, Paving the Way for a New Lung Cancer Treatment Apr. 9, 2025 — Researchers have discovered that 'DEAD ...

A new technique to mark peripheral pulmonary lesions (PPLs) before surgical resection was studied by Ganesh Krishna, M.D., a ...

Patients in Medicaid expansion states had more timely treatment, a study from the Houston-based University of Texas MD Anderson Cancer Center found. The study, published April 11 in The Annals of ...

Kim acted as her brother’s caretaker as Tony was mute and living with lung cancer, but as she went to check on him at his South Shore apartment, she made the heartbreaking discovery. " ...

And these sustained declines in lung cancer have been a major contributor to the overall improvements in cancer death. However, incidence rates are on the rise for several other cancers ...

Since the application of molecular biology in cancer biology, lung cancer research has classically focused on molecular drivers of disease. One such pathway, the hypoxic response pathway ...

However, an early-detected lung cancer, namely stage IA (T1, N0, M0) that is treated with resection may portend a long-term survival of 80% or better. [8–10] Therefore, it is of utmost ...

"While the overall survival rates for patients with non-small cell lung cancer have significantly improved in recent years, lung cancer continues to be the leading cause of cancer death worldwide ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).